Soligenix Reports 2025 Progress on Rare Disease Pipeline with Key Phase 3 Trial Milestones Approaching

Soligenix reported 2025 financial and operational results that demonstrate substantial progress across its rare disease development pipeline, with several key milestones expected in 2026. The company highlighted advancement of its Phase 3 FLASH2 trial evaluating HyBryte for cutaneous T-cell lymphoma, with interim analysis anticipated in the second quarter of 2026 and top-line results expected in the second half of the year. This trial represents a critical step toward potential regulatory approval for a novel photodynamic therapy utilizing safe visible light for this rare cancer.

The company also noted regulatory momentum with orphan drug designation granted for dusquetide in Behcet’s Disease, a rare inflammatory disorder. This designation provides certain development incentives and market exclusivity benefits if approved. Soligenix continues development of SGX302 for psoriasis and SGX945 for Behcet’s Disease, expanding its portfolio of treatments for conditions with significant unmet medical needs. The company reported a year-end cash position of approximately $7.9 million and stated it continues to pursue strategic options to support late-stage development activities.

Soligenix’s Specialized BioTherapeutics business segment focuses on developing HyBryte as a novel photodynamic therapy for cutaneous T-cell lymphoma. With successful completion of the second Phase 3 study, the company plans to seek regulatory approvals to support potential commercialization worldwide. The development programs in this segment also include expansion of synthetic hypericin into psoriasis and dusquetide for inflammatory diseases including oral mucositis in head and neck cancer.

The company’s Public Health Solutions business segment includes vaccine development programs supported by government funding from agencies including the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority. These programs incorporate the company’s proprietary heat stabilization platform technology known as ThermoVax®. Additional information about the company is available in its newsroom at https://ibn.fm/SNGX.

The progress reported by Soligenix represents important developments for rare disease patients who often have limited treatment options. The advancement of HyBryte through Phase 3 trials brings potential new therapy closer to patients with cutaneous T-cell lymphoma, while orphan drug designations for conditions like Behcet’s Disease signal regulatory recognition of the need for specialized treatments. As the company moves toward potential commercialization decisions in 2026, these developments could significantly impact treatment landscapes for multiple rare conditions. Investors and stakeholders can review the full terms of use and disclaimers applicable to all content provided by IBN at http://IBN.fm/Disclaimer.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Soligenix Reports 2025 Progress on Rare Disease Pipeline with Key Phase 3 Trial Milestones Approaching.

The post Soligenix Reports 2025 Progress on Rare Disease Pipeline with Key Phase 3 Trial Milestones Approaching appeared first on citybuzz.